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Abstract
Objective—Much of the genetic basis for Alzheimer disease (AD) is unexplained. We sought to 
identify novel AD loci using a unique family-based approach that can detect robust associations 
with infrequent variants (minor allele frequency <0.10).
Methods—We conducted a genome-wide association study in the Framingham Heart Study 
(FHS) (discovery) and NIA-LOAD (replication) family-based cohorts using an approach that 
accounts for family structure and calculates a risk score for AD as the outcome. Links between the 
most promising gene candidate and AD pathogenesis were explored in silico as well as 
experimentally in cell-based models and in human brain.
Results—Genome-wide significant association was identified with a PLXNA4 SNP (rs277470) 
located in a region encoding the semaphorin-3A (SEMA3A) binding domain (meta-analysis p 
value [meta-P]=4.1×10−8). A test for association with the entire region was also significant (meta-
P=3.2×10−4). Transfection of SH-SY5Y cells or primary rat neurons with full-length PLXNA4 
(TS1) increased tau phosphorylation when stimulated by SEMA3A. The opposite effect was 
observed when transfected with shorter isoforms (TS2 and TS3). However, transfection of any 
isoform into HEK293 cells stably expressing APP did not result in differential effects on APP 
processing or Aβ production. Late-stage AD cases (n=9) compared to controls (n=5) had 1.9-fold 
increased expression of TS1 in cortical brain tissue (P=1.6×10−4). Expression of TS1 was 
significantly correlated with the Clinical Dementia Rating score (ρ=0.75, P=2.2×10−4), plaque 
density (ρ=0.56, P=0.01) and Braak stage (ρ=0.54, P=0.02).
Interpretation—Our results indicate that PLXNA4 has a role in AD pathogenesis through 
isoform-specific effects on tau phosphorylation.
INTRODUCTION
Alzheimer disease (AD) is the most frequent age-related dementia affecting 5.4 million 
Americans including 13% of people ages 65 and older and over 40% of people ages 85 and 
older.1 Genetic factors account for much of the risk for developing AD with heritability 
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estimates between 60% and 80%.2 The apolipoprotein E (APOE) ε4 allele is a well-
recognized major risk factor for late onset AD, increasing the odds of disease in a dose-
dependent fashion.3 Common polymorphisms in 19 additional genes have been robustly 
established as risk factors for AD using large-scale genome-wide association studies 
(GWAS) and meta-analyses.4 These polymorphisms link to mechanisms of Aβ metabolism, 
lipid metabolism, inflammation, and axon guidance.5, 6 However, the heritability of AD 
explained by APOE is less than 30% and by each of the novel GWAS loci is less than 1%, 
suggesting that less than 50% of the genetic contribution to AD is explained by known 
common polymorphisms.4, 7, 8 The remaining heritability may be due to additional common 
variants of weaker effect, rare variants, copy-number variants, insertion-deletion 
polymorphisms, and gene-gene and gene-environment interactions.9, 10
Here, we conducted a two-stage family-based AD GWAS using a novel method which 
incorporates the entire family structure and reduces diagnostic misclassification in the 
association test, and renders a result that is less prone to type I error, even for rare variants.11 
We obtained strong evidence of association in the Framingham Heart Study (FHS) dataset 
with several SNPs in PLXNA4, a gene which had not been previously linked to AD. Several 
other PLXNA4 SNPs were highly significant in the National Institute on Aging-Late-Onset 
Alzheimer Disease (NIA-LOAD) study dataset. Subsequent in silico and molecular studies 
demonstrated isoform-specific effects of PLXNA4 on hyperphosphorylation of tau protein, a 
terminal step leading to breakdown of neuronal signaling and microtubule formation.
MATERIALS AND METHODS
Study Cohorts
Framingham Heart Study (FHS) discovery cohort—The FHS is a multigenerational 
study of health and disease in a prospectively followed community-based sample. Details on 
procedures for assessing dementia and determining AD status in this cohort are described 
elsewhere.12 We included only incident AD cases who had a magnetic resonance imaging 
(MRI) scan prior to disease onset. Clinical, demographic, genetic and pedigree information 
were obtained from dbGaP (http://www.ncbi.nlm.nih.gov/gap). Phenotypic and genome-
wide association study (GWAS) data were available for 61 cases and 2,530 cognitively 
normal controls from 1,232 families. This sample contained 287 parent-offspring pairs, 
1,215 sibpairs, 236 avuncular pairs, 714 cousin pairs, and 436 spouse pairs. The 61 AD 
cases are members of 57 families and three of these families contained distantly related 
affected individuals included in the analyses. Sixteen families did not have any genotyped 
AD cases but contained individuals with a history of dementia.
National Institute on Aging – Late Onset Alzheimer's Disease (NIA-LOAD) 
replication cohort—The NIA-LOAD Study recruited families with two or more affected 
members available for genotyping.13 Phenotype and GWAS data for this cohort were 
obtained from dbGaP. The GWAS dataset included a total of 1,819 AD cases and 1,969 
unaffected individuals from 2,265 families. The 1,819 AD cases are distributed among 988 
families containing 1,010 concordantly affected, 878 discordantly affected, and 541 
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concordantly unaffected sibpairs. Within the GWAS dataset, there were 526 parent-offspring 
pairs, 2,429 sibpairs, 1,905 avuncular pairs, 1,533 cousin pairs, and spouse pairs.
Alzheimer's Disease Genetics Consortium (ADGC) replication cohort—We 
obtained summarized results for SNPs located in the top-ranked locus from each of the 
individual ADGC datasets (excluding the NIA-LOAD dataset) which are described 
elsewhere.7, 14, 15 This sample included 18,901 Caucasians (9,966 cases and 8,935 controls), 
4,896 African Americans (1,459 cases and 3,437 controls), and 1,845 Japanese (951 cases 
and 894 controls).
Genotyping, Quality Control, Population Substructure, and Imputation
FHS samples were genotyped at Affymetrix (Santa Clara, CA) using the Affymetrix 
GeneChip® Human Mapping 500K Array Set and 50K Human Gene Focused Panel®.16 
NIA-LOAD samples were genotyped using Illumina 610 high-density SNP microarrays.7 
APOE genotypes were obtained by restriction fragment length polymorphism analysis for 
the FHS cohort and by haplotype analysis of SNPs rs7412 and rs429358, which were 
genotyped at Prevention Genetics (http://www.preventiongenetics.com) for the NIA-LOAD 
cohort.
Quality control (QC) procedures and analysis of population substructure were performed as 
previously described.17 In the discovery genome-wide association (GWA) dataset, 341,492 
SNPs genotyped in 2,591 subjects passed QC. Based on this number of SNPs, the threshold 
for genome-wide significance was P=1.46×10−7.
In candidate gene analyses in the FHS and NIA-LOAD datasets, we evaluated SNPs within 
50 kb of the top-ranked gene from the discovery GWA study that were imputed previously 
using the HapMap 2 CEU reference panel and the MaCH program.17, 18 SNPs with an 
imputation quality measure (RSQ)<0.80 were excluded.
Statistical Analysis
AD risk scores—We calculated AD risk scores using two different approaches. In the 
FHS dataset, liability scores are residuals from a logistic regression model for AD affection 
status adjusting for sex and censoring age (age at onset of AD or age at exam of controls) 
evaluated using R.17 We did not adjust for previously derived principal components (PCs) of 
population substructure because they were not significantly associated with the liability 
scores in the FHS dataset.19 In the NIA-LOAD dataset, we calculated liability scores 
(residuals) from a logistic regression model for AD affection status adjusting for sex, 
censoring age, and the first two genotype-covariance matrix PCs to account for population 
substructure. We also computed propensity scores in the NIA-LOAD dataset to account for 
the approximately 10-year lower mean age of this cohort compared to the FHS cohort and 
ascertainment of families with multiple affected members. This method was suggested 
previously for analysis of a binary trait with various ages at onset and exam among affected 
and unaffected subjects, respectively.20, 21 Propensity scores were obtained for unaffected 
family members using the AGEON program in S.A.G.E. (v6.2)22 as the probability of 
getting disease conditioned on affection status and censoring age of their parents. Affection 
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status for AD cases (probability=1) was retained in the model. Propensity scores were 
further adjusted for censoring age, sex, and the first two PCs in a linear regression model, 
and the residuals used as the outcome variable. We were unable to obtain propensity scores 
in the FHS dataset because of incomplete parental information.
SNP association test—The quantitative risk scores (residuals from liability or propensity 
scores) were normalized by taking the inverse standard normal transformation of the 
empirical quantile that was obtained using the formula [r(y)−1/3] divided by (n+1/3), where 
r(y) is the rank of residuals, y. This approach has been demonstrated to be valid for family-
based association tests even for a binary trait with rare variants.23 Association of the 
normalized risk scores with each SNP was evaluated using the extension of the two-level 
Haseman-Elston regression method implemented in the RELPAL program in S.A.G.E. 
(v6.1).24, 25 Models included a term for an inheritance vector of exhaustive relative pairs. 
Nominal P values for association were determined using first-level Wald tests. For top-
ranked genes, we conducted association tests for genotyped and well-imputed SNPs (RSQ ≥ 
0.8) in the FHS and the NIA-LOAD datasets using a risk score (i.e., liability score or 
propensity score) as a quantitative trait.
Regional association test—To allow for the possibility of allelic heterogeneity between 
the two family datasets, we performed association tests within each dataset for regions in the 
top ranked gene defined by the ligand-binding domain of the encoded protein using the 
Versatile Gene-Based Association Study (VEGAS) program which calculates p values based 
on 100,000 permutations.26
Meta-analysis—Results from the FHS and NIA-LOAD datasets were combined by meta-
analysis of Z-scores weighted by the number of subjects using METAL.27 In region-based 
meta-analysis, we assumed the same direction of effect on a region in both datasets and 
combined results using the Z-score approach. The summary results for the ADGC datasets 
(excluding the NIA-LOAD study) were meta-analyzed using the inverse variance method in 
METAL after applying a genomic control within each individual dataset.7
APP and Amyloid β (Aβ) Analyses
Cell maintenance and transfection—HEK293 cells stably transfected with wild type 
APP751, were maintained as previously described.28 The day before transfection, cells were 
split into 6 well plates at a density of 1×105 cells per well. The cells were transfected with 
EV (empty vector) or PLXNA4 isoforms (TS1, TS2, or TS3) from OriGene using Attractene 
(Qiagen). Forty-eight hours post transfection, media were collected and cells were lysed as 
described.28
SDS-PAGE and western blotting—Proteins were separated on 8% Tris-Glycine gels 
and transferred onto nitrocellulose (Millipore). Primary antibodies were mouse monoclonal 
6E10 (Covance, 1:1000) against amino acids 1–17 of Aβ that also recognize full length APP 
and APPsα, anti-Myc mAb (Sigma, 1:1000) and mouse monoclonal beta-tubulin 
(Invitrogen, 1:10,000). Secondary antibody was peroxidase labeled goat anti-mouse IgG 
(KPL, 1:500). The Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific) 
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was used for detection. Protein expression was analyzed by densitometry using ImageJ 
software. The expression of APPsα was normalized to total APP.
Aβ enzyme-linked immunosorbent (ELISA) assay—Forty-eight hours after 
transfection of HEK293 cells (stably transfected with wtAPP751) with EV or PLXNA4 
isoforms (TS1, TS2, or TS3), media were collected and centrifuged at 16,873g for 5min at 
4°C to discard cell debris. ELISAs were carried out using the human Aâ40 and Aâ42 ELISA 
kits (Invitrogen) in accordance with manufacturer's protocol with samples diluted 1:2 in 
diluent buffer and as previously described.28
Tau Analyses
Tau immunoblotting—SH-SY5Y cells (2×106) stably expressing mutant tau P301L (SH-
SY5Y P301L) were transfected with 1 μg of various Plexin-A4-Myc or pcDNA3 vectors by 
lipofectamine 2000 (Invitroge, Corp., Carlsbad, CA). After transfection, cells were treated 
with or without 3nM Semaphorin3A (Sema3A-FC, R&D Systems) for 1 hour. Twenty g of 
whole cell lysate were immunoblotted with phospho-tau (AT-8, 1:500), total-tau (Tau46, 
1:500), β-actin (1:1000), or Myc (9E10, 1:1000) as previously described.29
Pull-down assay—Plexin-A4-Myc transfected SH-SY5Y P301L cells were treated with 
3nM 6xHis human Sema3A-FC in DMEM/F12/B-27 medium. After Sema3A-FC 
stimulation, the media were collected and the Sema3A-FC was precipitated with Protein 
A/G agarose, followed by immunoblotting of the samples for Myc (9E10, for detection of 
Plexin-A4 molecules) and 6x His (H-3, for detection of Sema3A, 1:1000, Santa Cruz 
Biotech).
Primary neuron culture and tau immunofluorescence—Rat primary hippocampal 
neurons were harvested from E18 embryonic brain, plated on poly-D-lysine coated 
coverslips, cultured for 14 days, and transfected with full-length or short isoforms of human 
Plexin-A4-Myc DNA plasmid vectors by lipofectamine 2000 (Invitrogen). Twenty-four hrs 
after transfection, cells were treated with or without 3 nM Semaphorin3A (Sema3A-FC) for 
1-hr, fixed with 4% paraformaldehyde, and co-stained with T514 phosphorylated collapsing 
response mediator protein 2 (pT514 CRMP2, Ab62478, rabbit polyclonal 1:500, Abcam) 
and β3-tubulin (mouse monoclonal 1:500, Promega), or co-stained with AT8 (mouse 
monoclonal, 1:500) and anti-Myc (rabbit polyconal, 1:200, Covance Inc), followed by 
incubation with anti-mouse IgG Alexa 568 conjugated goat secondary antibody (1:600, 
Invitrogen) and anti-rabbit IgG Alexa 488 conjugated goat secondary antibody (1:600, 
Invitrogen). Immunostained AT8 signals were digitally captured using an inverted 
fluorescence microscope (TE-2000U, Nikon Instruments, Melvin, NY) and quantified by 
ImageJ (NIH shareware program). Data were obtained from at least 100 cells in three 
independent experiments.
Analyses of Gene Expression in Brain
Gene expression experiments were conducted on brain tissue specimens obtained from 17 
autopsied subjects including five controls (Braak stage 0), five early-stage AD cases (Braak 
stages 1–2), and nine late-stage AD cases (Braak stages 3–4). Ascertainment, cognitive 
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assessment, neuropathological assessment, and stratification of these subjects were 
previously described.30 Frozen post-mortem brain tissue specimens from Brodmann area 9 
of subjects were obtained from the Mount Sinai/Bronx Veterans Administration (VA) 
Medical Center/Department of Psychiatry Brain Bank. Normal controls had no history of 
any psychiatric or neurological disorders and no discernible neuropathological lesions. The 
Institutional Review Boards of Pilgrim Psychiatric Center, the Icahn School of Medicine at 
Mount Sinai, and the Bronx VA Medical Center approved all assessment and post-mortem 
procedures.
Total RNA was isolated from 50 mg of tissue by using the Qiagen miRNeasy kit. Isolated 
RNA samples were treated with 40 units of DNase I (Ambion) to remove genomic DNA 
contamination. Template RNA quantity and quality, including degradation, were determined 
on an Agilent 2100 Bioanalizer. Two samples with very low RNA integrity number were 
excluded from the study. After cDNA synthesis using Superscript III first-strand synthesis 
kit (Invitrogen, Carlsbad, CA), qPCR were run on an ABI 7900HT real-time machine in 
triplicate using Platinium Quantitative PCR SuperMix-UDG (Invitrogen, Carlsbad, CA) for 
primers designed with the Roche Universal Probe Library or SYBR GreenER qPCR 
supermix for regular primers for ABI PRISM (Invitrogen). Acquired data were loaded onto 
qBase ver.1.3.5 software for quality control and normalization to reference genes GAPDH 
and RPL13A.
Group differences between TS1 and TS3 or between controls and AD cases were evaluated 
using ANOVA and the appropriate T-test after checking for equality of variances. Pearson 
correlations were calculated using the SPSS program. Although post-mortem intervals 
(PMI) among AD cases and controls were comparable (P=0.450), we repeated the analyses 
including PMI as a covariate because differences in PMI can affect brain biochemistry and 
quality of RNA. Since results from models with and without PMI were similar, we reported 
only the results without adjustment for PMI.
RESULTS
Genome-Wide Association
The mean onset age of AD among the 61 incident cases in the FHS dataset was about 10 
years older than that for the 1,819 AD cases in the NIA-LOAD dataset (Table 1). The 
frequency of APOE ε4 carriers in affected subjects was approximately two times greater in 
the NIA-LOAD cohort compared to the FHS cohort. In addition, the proportion of APOE ε4 
carriers in controls was 15% less in the FHS cohort. Among the 1,969 unaffected family 
members in the NIA-LOAD cohort, 439 had propensity scores of at least 80% (i.e., risk to 
develop AD accounting for parental affection status and age at onset/exam) and 809 had 
propensity scores of zero indicating true controls.
Analysis of genotyped SNPs (n=341,492 post quality control) in the FHS dataset using the 
normalized liability scores for AD (Fig 1A) indicated little genomic inflation (λ=1.01, Fig 
1B) with strong evidence of association in three regions of the genome (Fig 1C). Genome-
wide significant associations were found with SNPs in ITIH3 (rs9311482: β=1.3, 
P=5×10−9), PLXNA4 (rs277484: β=1.1, P=9×10−10) and MYO18B (rs13057714: β=1.0, 
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P=9×10−9). SNPs located in IGSF21 were suggestive at P<10−6 (Supplementary Table 1). 
Each dose of the minor alleles for these SNPs increased AD liability by at least one rank unit 
(mean liability on the normalized scale). Based on an ad hoc power calculation using the 
sibling correlation of 0.2 derived from the data, the observed effect sizes and minor allele 
frequencies (MAF), and a genome-wide significance level of 1.46×10−7, the FHS dataset 
had between 60% and 95% power to obtain these results even for infrequent SNPs 
(0.01<MAF<0.05) (Fig 2). Among the previously known genes for AD, one genotyped SNP 
in BIN1 was moderately associated with the liability score (rs10180840, P=1.4×10−4). We 
attempted to discover additional association signals in IGSF21, ITIH3, PLXNA4, and 
MYO18B by evaluating 1,515 genotyped and accurately imputed SNPs (RSQ≥0.8) in the 
FHS dataset (Supplementary Table 2). PLXNA4 SNPs rs277470, rs277472, rs277476, and 
rs277484 were significant (P<10−9 for each, Fig 3A) and in complete linkage disequilibrium 
(LD) with each other (Fig 4). Among the top PLXNA4 SNPs, only rs277484 was genotyped. 
No additional SNPs from the IGSF21, ITIH3 or the MYO18B met the significance threshold 
of 1.4×10−7. The dose of APOE ε4 alleles was not significantly associated with the AD 
liability score in FHS (P=0.24), perhaps because most of the incident cases in this cohort 
were observed at ages where the ε4 association with AD is relatively weak.3
Replication and Extended Analysis of PLXNA4
Next, we tested association of 746 genotyped and accurately imputed SNPs (RSQ≥0.8) from 
PLXNA4 in the NIA-LOAD dataset (Fig 3B), but were unable to replicate any of the top-
ranked SNPs obtained in the FHS sample (Supplementary Table 3). However, 16 of the 746 
PLXNA4 SNPs showed significant association at P<10−3 in a model using the normalized 
liability score, and these association signals were improved using the normalized propensity 
score (Supplementary Table 3). We observed an association trend in the same effect 
direction with rs277470 in the NIA-LOAD using the propensity score (p value: 
FHS=2.1×10−10, NIA-LOAD=0.06, meta-analysis=4.1×10−8) (Fig 3C). Each dose of the 
minor allele C for rs277470 increased the liability rank by at least one unit in FHS dataset 
and the propensity rank by 13% in NIA-LOAD (Table 2). The most significant finding in 
NIA-LOAD (Fig 3B) was obtained with a genotyped SNP rs12539196 (p value: FHS=0.114, 
NIA-LOAD=3.7×10−5, meta-analysis=2.8×10−5). The minor allele C for rs12539196 
decreased the liability rank by 0.09 in FHS and accounts for a 15% reduction in the 
propensity rank in NIA-LOAD (Table 2). The result for rs12539196 in the NIA-LOAD 
dataset was not meaningfully changed after adjustment for the number of APOE ε4 alleles 
(P=2.7×10−5) and remained significant after correction for multiple testing (P=0.0036).
Further scrutiny of the PLXNA4 findings revealed that the most significant SNPs in each 
dataset are clustered in two distinct regions between recombination hot spots (Fig 3A to C), 
are separated by approximately 78,240 base pairs apart in intron 2 of the largest transcript 
(TS1), and flank an alternatively spliced exon present only in a much shorter transcript 
(TS3) (Fig 3D). Bioinformatic evaluation revealed that TS1 contains a transmembrane 
domain, whereas the shorter isoforms are predicted to be secreted (Fig 3E), suggesting that 
the longer and shorter isoforms may have distinct functional consequences related to AD. 
Based on this information, we performed region-based analyses including only SNPs located 
between 131,925,825 and 132,193,452 base pairs (including all of intron 2) encompassing 
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the SEMA domain (Fig 3E), and confirmed significant association for the region (Table 2) in 
both datasets (p value: FHS=6.3×10−3; NIA-LOAD=0.019; meta-analysis=3.2×10−4).
Association with PLXNA4 was further examined using meta-analyzed results in the ADGC 
datasets. The most significant SNPs in each population under the additive model were 
rs10273901 in Caucasians (minor allele frequency [MAF]=0.42; meta-analysis p value 
[meta-P]=3.9×10−5; odds ratio [OR]=0.85, 95% Confidence Interval [95% CI]: 0.79–0.92), 
rs75460865 in African Americans (MAF=0.04; meta-P=8.0×10−4; OR=1.55, 95% CI: 1.20–
2.01), and rs13232207 in Japanese (MAF=0.19; P=1.2×10−4; OR=1.51, 95% CI: 1.22–1.86). 
The results for the Caucasian and Japanese groups remained significant after correcting for 
multiple testing (P=0.013 and P=0.037, respectively). Rs75460865 is located in the portion 
of the sequence which encodes the SEMA domain, but rs10273901 and rs13232207 are 
located in the PLXNA4 region that encodes the CYTO domain (Fig 3E). Top ranked SNPs 
in the FHS and NIA-LOAD datasets were not associated in the other ADGC datasets 
(P>0.1) likely because power to detect association with several SNPs (including rs277470) 
having low minor allele frequencies is weaker in the ADGC datasets compared to large 
extended family-based samples. Because the LD structure in this region is similar across 
populations (Fig 4), different association peaks among these groups is consistent with the 
existence of multiple distinct functionally-relevant AD-related alleles. In summary, the 
results in each of the ADGC ethnic samples support the association of AD with PLXNA4 
SNPs.
PLXNA4 Does Not Influence APP Processing or Aβ Production
To determine whether PLXNA4 isoforms are differentially involved in APP processing and 
Aβ production, we transfected HEK293 cells stably expressing APP751 with empty vector 
control (EV) or with the full-length (TS1) or one of the shorter isoforms (TS2 and TS3) of 
PLXNA4-Myc and analyzed total APP in cell lysates, and APPsα, Aβ40, and Aβ42 in the 
medium. Neither over-expressing PLXNA4 isoforms affected APPsα secretion (Fig 5A and 
B) or Aβ40 and Aβ42 production (Fig 5C). These results suggest that PLXNA4 is not 
involved in AD through the non-amyloidogenic or amyloidogenic processing of APP.
PLXNA4 Isoforms Differentially Affect Tau Phosphorylation
Involvement of plexin-A4 signaling in tau phosphorylation was examined by transfecting 
cDNAs for the full-length (TS1) or 3' C-terminal truncated short isoforms (TS2 and TS3) of 
human PLXNA4-Myc into SH-SY5Y P301L cells (SH-SY5Y cells stably expressing the 
P301L tau mutant) and stimulated with or without 3 nM recombinant Semaphorin-3A 
(SEMA3A-FC). Immunoblotting with AT8 (anti-phospho-Tau at Ser202/Thr205) showed that 
tau phosphorylation was induced by SEMA3A stimulation, which was enhanced by over-
expression of TS1 (Fig 6A). In contrast, over-expression of either TS2 or TS3 inhibited tau 
phosphorylation under stimulation by SEMA3A (Fig 6A). Since TS2 and TS3 are secretory 
molecules with the SEMA3A binding site in the extracellular domain, we assume that the 
inhibitory effect is mediated by the competitive binding of the short isoforms to SEMA3A. 
Pull-down assays confirmed that the short isoforms, but not full-length PLXNA4, 
specifically co-precipitated with SEMA3A in the media (Fig 3B). These data demonstrate 
that the short isoforms are secreted as expected and bind to SEMA3A thereby inhibiting 
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signaling. To confirm that SEMA3A/PLXNA4 signaling phosphorylates endogenous wild 
type tau protein, we repeated the experiment in rat primary hippocampal neurons. SEMA3A 
activated PLXN signaling leading to phosphorylation of endogenous CRMP2 at Thr 514 by 
glycogen synthase kinase-3β was confirmed in the primary cultured hippocampal neurons 
(Fig 6C). Stimulation of neurons with SEMA3A induced phosphorylation of endogenous tau 
as determined by AT8+ cells (Fig 6D, red staining in Myc− cells). Transient expression of 
Myc-tagged full-length PLXNA4 significantly elevated SEMA3A-induced endogenous tau 
phosphorylation (Myc+ AT8+ cells) as compared to untransfected neurons (Myc− AT8+ 
cells, p < 0.01), while expression of Myc-tagged shorter isoforms significantly reduced 
SEMA3A-induced tau phosphorylation in neurons (Fig 6D). This demonstrates that 
SEMA3A/PLXNA4 signaling phosphorylates endogenous tau in an isoform-specific 
manner.
Expression of PLXNA4 in Brain is Different in AD Cases and Controls
Expression of the TS1 and TS3 was quantified in brain tissue specimens from the middle 
frontal gyrus (Brodmann area 9) from 19 autopsied subjects including five controls, five 
early-stage AD cases, and nine late-stage AD cases (Supplementary Table 4) using the 
primer sets shown in Supplementary Table 5. Late-stage AD cases compared to controls had 
1.9-fold increased expression of TS1 (P=6.0×10−4) and a more modestly increased 
expression of TS3 (P=0.021) and ratio of TS1/TS3 (P=0.066) (Fig 7). These patterns were 
similar in the comparison of all AD cases to controls (P-value: TS1=0.003, TS3=0.097, TS1/
TS3=0.18) and are not age-related (Table 3). In the combined sample of AD cases and 
controls, TS1 level was significantly correlated with the clinical dementia rating score 
(ρ=0.75, P=2.2×10−4) and several measures of AD neuropathology (ρ≈0.5, P<0.05), but the 
correlations of TS3 level with these traits were much smaller (Table 3). These findings 
suggest that elevation in TS1 level increases risk for developing AD.
DISCUSSION
We identified significant association between AD risk and SNPs in PLXNA4 using a family-
based approach. The top-ranked SNPs in the discovery and replication datasets are located in 
a single intron and surround an exon that is skipped in the processing of the full-length 
mRNA transcript. We also demonstrated that the full-length isoform (TS1), but not the 
shorter isoforms (TS2 and TS3) of PLXNA4 increased tau phosphorylation in SH-SY5Y 
cells stably expressing the P301L tau mutant and in primary rat neurons when stimulated by 
SEMA3A. Significantly higher levels of TS1 and TS3 in cortical brain tissue were observed 
in late-stage AD cases compared to controls. By comparison, transfection of either isoform 
into HEK293 cells stably expressing APP failed to show differential effects on APP 
processing or Aβ production. Taken together, our results indicate that PLXNA4-mediated tau 
phosphorylation is an independent upstream event leading to AD-related tangle formation in 
neurons.
PLXNA4 is a member of a family of receptors for transmembrane, secreted and GPI-
anchored semaphorins in vertebrates31 and is a receptor for secreted semaphorin class 3 
(SEMA3A) and class 6 (SEMA6) proteins which play an important role in semaphorin 
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signaling and axon guidance.32 Accumulation of SEMA3A was previously detected in 
susceptible areas of the hippocampal neurons during AD progression and colocalized with 
phosphorylated tau.33 A phosphorylated CRMP2 protein, an intracellular signaling molecule 
for the semaphorin-plexin signaling pathway, has been observed in neurofibrillary tangles in 
brains of autopsied AD patients.34 The staining pattern of SEMA6, which is present in fibers 
and nerve terminals, is disrupted in brains of patients with AD.35 These reports and our 
study collectively indicate that disrupted semaphorin-plexin signaling is involved in AD 
pathogenesis, specifically through tau phosphorylation leading to tangle formation and 
neuronal death. Semaphorin-plexin signaling is known to regulate axon guidance in the 
development of sympathetic nervous system and cerebral cortex.36–38 Binding of SEMA3A 
to truncated PLXNA proteins was demonstrated to have a dominant negative effect on 
cortical growth cone collapse.39 Our data indicate that disruption of this signaling may also 
contribute to the acceleration of tau phosphorylation leading to neurofibrillary tangle 
formation. A recent whole exome sequence study identified a rare coding PLXNA4 variant 
in two distantly related individuals with familial Parkinson disease (PD).40 Notably, both PD 
subjects were cognitively impaired and there is a recognized form of PD with dementia. 
Further screening of all PLXNA4 exons in a large sample of unrelated PD cases and controls 
revealed a large number of very rare coding variants unique to cases or controls. Although 
the pathogenicity of these variants is yet unknown, this study provides additional evidence 
supporting PLXNA4 as a common biological pathway leading to AD and PD. Taken 
together, our findings point to a novel mechanism for AD-related tangle formation, implying 
that reduced expression of PLXNA4, and the TS1 isoform in particular, in brain is crucial to 
maintain healthy neurons.
There are three known alternatively spliced PLXNA4 transcripts. The full-length transcript 
(TS1) contains 31 exons and encodes an isoform with 1,894 residues. Two alternatively 
spliced transcripts each contain three exons yielding shorter isoforms of 522 residues (TS2) 
and 492 residues (TS3). The distinct PLXNA4 association peaks in the discovery and 
replication datasets flank an exon that is present only in TS3. A direct link of PLXNA4 
expression to AD is supported by evidence in this report of increased expression of TS1 and 
TS3 isoforms in post-mortem neuronal tissue from AD cases compared to controls. 
Importantly, the findings that the relative increase of TS1 is much greater than TS3 in AD 
cases, and TS1 expression is significantly correlated with clinical and neuropathological 
severity measures of AD, are consistent with our observation of increased phosphorylation 
of tau by SEMA3A bound specifically to TS1.
Previous GWA studies involving the FHS dataset have successfully identified several AD 
genes including BIN1, MS4A4/MS4A6A, EPHA7, ABCA7, CD33, CD2AP, HLA-DRB5–
HLA-DRB1, PTK2B, SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, 
FERMT2, and CASS4,4, 16, 41 but the portion of evidence for these associations attributable 
to the FHS dataset is very small and the robust associations with these loci are with common 
SNPs (MAF > 0.08) each exerting a small effect on risk (OR ≤ 1.2). We increased the 
potential for gene discovery in the FHS and NIA-LOAD datasets by applying an analytical 
method that leverages the family structure that is otherwise ignored when using Generalized 
Estimating Equations (GEE) models. Our approach is applicable to extended pedigrees and 
is robust for detecting association with infrequent SNPs (0.01≤MAF<0.1) because the power 
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for this method is largely dependent on effect size rather than allele frequencies.11 Except 
for BIN1, lack of significant associations with most of the previously known AD loci 
suggests that they do not contain large effect variants for AD risk in the range of infrequent 
MAFs. In addition, we addressed phenotype misclassification by including only incident 
cases with known onset ages in the FHS dataset and by using the propensity score approach 
in the NIA-LOAD dataset which has a skewed distribution of onset ages and is enriched 
with familial AD cases. Our method using propensity scores as a surrogate for AD 
susceptibility assigned probabilities greater than 50% for future development of AD to 60% 
of the unaffected subjects at last exam in the NIA-LOAD cohort. This indicates that analyses 
using affection status in families with multiple affected members have much less power to 
detect true associations without adjusting for misclassification of unaffected relatives.
Our study has several caveats. Power to detect association with AD risk is low in the FHS 
cohort because of the small number of incident cases. We overcame this limitation by using 
a continuous measure of AD liability instead of AD status as the outcome. In addition, the 
top-ranked PLXNA4 SNPs were not the same across datasets and thus the lack of an exact 
replication may indicate that the initial finding was a false positive. However, the inability to 
replicate at the SNP level can be explained by differences in allele frequencies across 
populations, and low power and reliability to detect association with infrequent SNPs in 
samples of unrelated cases and controls. Another likely contributor to the different 
association patterns is allelic heterogeneity, which we observed for SORL142 and has been 
reported among Caucasians for other common diseases.43, 44 Nevertheless, our PLXNA4 
region-based test results were significant in both FHS and NIA-LOAD datasets. Moreover, 
the observed effects of PLXNA4 isoforms on AD-related processes in cultured neuronal 
cells and brain, which were identified through experiments conducted because of the 
association findings, suggest that the significant results with individual PLXNA4 SNPs are 
not false positives. Another concern is that we did not have genotypes for the top ranked 
SNPs in a large sample of AD cases and controls with brain tissue available for study. As a 
result, we were unable to investigate allele specific effects on isoform expression levels. 
Moreover, demonstration of higher isoform levels in peripheral tissue of living AD cases 
compared to controls would lessen the concern that the differences observed in brain are not 
secondary to underlying pathology. In addition, in vitro tau phosphorylation experiments do 
not indicate which tau kinases activate tau phosphorylation. Cycline-dependent kinase 5 and 
glycogen synthase kinase-3β are known to be activated by SEMA3A by phosphorylating 
CRMP2 to mediate growth cone collapse.45, 46 It is most likely that PLXNA4 induces tau 
phosphorylation via activation of these two established kinases. Also, because these results 
are based on the transient expression of PLXNA4 molecules, it is crucial to evaluate the 
influence of PLXNA4 on tau phosphorylation in more physiological conditions. Isoform-
specific targeting of PLXNA4 in mice is a potential future study in vivo.
In summary, our novel genetic association findings and results of molecular and cell biology 
experiments in cell lines, rat neurons, and human brain demonstrate that PLXNA4 is 
involved in AD pathogenesis. Evidence supporting transcriptional regulation of PLXNA4 
isoforms that have differential effect on tau phosphorylation and, hence, tangle formation 
suggests the potential for a new drug target. These findings warrant follow-up experiments 
to delineate the upstream factors governing PLXNA4 binding to CRMP2, ascertain the 
Jun et al. Page 12
Ann Neurol. Author manuscript; available in PMC 2016 April 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
causative genetic variants at the two association peaks and determine how they modulate 
expression of the individual isoforms, demonstrate in brain tissue that the genetic variation 
in PLXNA4 is associated with AD risk or progression, and evaluate the utility of PLXNA4 
as a potential biomarker for AD. Further studies of PLXNA4 may also provide mechanistic 
evidence linking AD to PD with comorbid dementia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Genome-wide association analysis in the Framingham Heart Study
(A) Ranked risk score distribution. Liability scores after adjusting for age and sex in a 
logistic regression model were rank-transformed and analyzed as a quantitative trait. Areas 
with red indicate distribution of risk (liability) rank of AD cases based on age at onset. Black 
arrow for age at exam from controls and red arrow for age at onset from AD cases indicate 
ranks of risk scores. The curve shows younger unaffected subjects have higher risk to 
develop AD than older unaffected subjects, and AD cases with earlier onset have greater 
liability than cases with older onset. (B) Quantile-quantile plot. Observed P values (Y-axis) 
were plotted against expected P values (X-axis). Black dots represent P values for all 
genotyped SNPs. (C) Manhattan plot. Association results for genotyped SNPs. P-values 
are expressed as −log10(P) (y-axis) for every tested SNP ordered by chromosomal location 
(x-axis). Genome-wide significance level is shown as a dotted line at P=1.4×10−7.
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Fig 2. Power to detect genome-wide significant association with AD in the Framingham Heart 
Study
Effect sizes (i.e., beta estimates in the regression model) to obtain 80% power for infrequent 
SNPs (0.01 ≤ minor allele frequency [MAF] ≤ 0.1) under the additive model were estimated 
using a sibling correlation of 0.199 in 2,779 relative pairs at the genome-wide significance 
level. Effect size of the SNP on AD risk (Y-axis) according to MAF (X-axis) was computed 
for rank-transformed liability scores. The power estimates are conservative because they 
account for only sib-pair relationships in the pedigree.
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Fig 3. Genetic findings in the PLXNA4 region
Regional association plots of genotyped and imputed SNPs from the FHS (A) and NIA-
LOAD (B) datasets, and in meta-analysis (C). Most significant SNPs in the FHS (rs277470) 
and NIA-LOAD (rs12539196) datasets are indicated by purple diamonds. P-values are 
expressed as −log10(P) (y-axis) for every tested SNP ordered by chromosomal location (x-
axis). Estimates of linkage disequilibrium (r2) of SNPs in this region with the top SNP 
computed using 1000 Genomes (hg19/Nov2010EUR) are shown as orange circles for r2 ≥ 
0.8, yellow circles for 0.5 ≤ r2 < 0.8, light blue circles for 0.2 ≤ r2 < 0.5, and blue circles for 
r2 < 0.2. Recombination rates (scale on right axis) are plotted with a solid gray line. 
Genomic structure of PLXNA4 was determined using the NCBI database (Build 37.1). (D) 
Relative position of the most significantly associated SNPs in FHS and NIA-LOAD datasets 
in the three validated transcripts (TS1, TS2, and TS3). Exons are denoted with horizontal 
bars. (E) Diagrams of functional domains encoded by amino acids from the full-length 
(TS1) and the shorter (TS2 and TS3) transcripts. SEMA: sema_plexinA1 interacting module 
(exon 1–4 in TS1 and exon 1–3 in TS2 and TS3); PSI: plexin repeat (exon 4–11 in TS1); 
IPT: three repeats of the binding domains of plexins and cell surface receptors (exon 11–17 
n TS1); PCSR: binding domain of plexins and cell surface receptors (PCSR) and related 
proteins (exon 17–19 in TS1); TM: transmembrane region (exon 19 in TS1); CYTO: 
cytoplasmic domain (exon 20–31 in TS1).
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Fig 4. Linkage disequilibrium (LD, D') of top ranked SNPs
LD was calculated in 1000 Genomes data from (A) Caucasians (CEU), (B) African 
Americans (AA), and (C) Asians (ASN). Top-ranked SNPs from PLXNA4 from each 
dataset are shown, namely rs277470, rs277472, and rs277484 in FHS; rs12539196 in NIA-
LOAD, rs10273901 in ADGC Caucasians (ADGC-EA), rs75460865 in ADGC African 
Americans (ADGC-AA), and rs13232207 in ADGC Japanese (ADGC-JPN). The top SNP in 
the ADGC-AA dataset was monomorphic in both CEU and ASN populations. Five top-
ranked SNPs (rs10273901, rs75460865, rs277470, rs277472, and rs277484) from the 
ADGC-EA and ADGC-AA samples were monomorphic in the ASN population. The top 
ranked SNPs are located in the SEMA domain, except rs10273901 and rs13232207 which 
are located in the cytoplasmic domain.
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Fig 5. Effect of expression of the full-length PLXNA4 isoforms (TS1, TS2 and TS3) on APP 
processing
HEK293 cells stably overexpressing APP were transiently transfected with empty vector 
control (EV) or with the full-length (TS1) or one of the shorter isoforms (TS2 and TS3) of 
PLXNA4-Myc. 48 hrs after transfection, the conditioned medium (medium) and the cell 
lysates (lysate) were collected and analyzed by SDS-PAGE and western blotting using mAb 
6E10 for total APP and APPsα, Myc mAb for all 3 isoforms of PLXNA4, and tubulin as 
control (A). The endogenous myc can be seen in all lanes at ~55 kDa but more clearly in 
lanes 7–9 where only empty vector was transfected but not PLXNA4-myc. Also note that 
TS1 migrates at 212kDa, TS2 migrates at 58kDa and TS3 migrates at 55kDa. (B) 
Densitometric analysis of the expression of APPsα normalized to total APP. Error bars 
indicate standard deviation. (C) ELISA analysis of Aβ40 and Aβ42 released to the medium. 
ELISAs were carried out using the human Aβ40 and Aβ42 ELISA kits (Invitrogen) in 
accordance with manufacturer's protocol. Error bars indicate standard deviation. 
Representative results of three independent experiments are shown in each panel.
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Fig 6. Effect of PLXNA4 isoforms on tau phosphorylation
(A) SH-SY5Y P301L cells were transfected with the full-length (TS1) or one of the shorter 
isoforms (TS2 and TS3) of PLXNA4-Myc or empty vectors (pcDNA3.1) with or without 
3nM SEMA3A stimulation for 1hr. Whole cell lysates were blotted with AT8, total tau, actin 
and Myc. Results for the TS2 and TS3 isoforms were similar but ony those for TS3 are 
shown. (B) 6x His-tagged SEMA3A-Fc was precipitated from media by Protein A/G 
agarose, and the precipitates were immunoblotted with antibodies to Myc (detecting 
PLXNA4 isoforms) and 6x His (detecting SEMA3A-FC). (C) E18 rat primary hippocampal 
neurons were cultured for 14 days and stimulated with 3nM SEMA3A for 1 hr, and co-
stained with anti-β3-tubulin (B3T) mouse monoclonal (1:500, green) and anti-pT514 
CRMP2 rabbit polyclonal (1:500, red). (D) Rat primary hippocampal neurons were 
transfected with the full-length or short isoforms of Plexin-A4-Myc. After transfection, cells 
were treated with or without 3 nM Sema3A for 1-hr, and co-stained with AT8 (1:500) and 
anti-Myc (rabbit polyclonal, 1:200, Covance Inc). AT8 signals were digitally captured and 
quantified as previously reported (Uchida et al., 2005). Cells are immunostained with anti-
Myc (green) and AT8 (red). Scale bar represents 10 μm. * P<0.05, ** P<0.01, and *** 
P<0.001, as determined by ANOVA and Tukey post hoc.
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Fig 7. Expression of PLXNA4 isoforms in postmortem brains
Expression of PLXNA4 isoforms from Broadmann area 9 of frozen post-mortem brain tissue 
specimens were compared in controls and late-stage AD cases using primer sets to detect 
full-length (TS1) and short (TS3) isoforms. RNA expression level (Y-axis) shown is the 
normalized value. P-values were determined by T-test accounting for unequal variances.
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Table 3
Correlation of PLXNA4 isoform levels with clinical and neuropathological phenotypes in brain specimens 
from subjects with AD and controls.
Characteristics
Correlation (P value)
TS1 TS2
Age 0.27 (0.27) 0.31 (0.20)
PMI −0.01 (0.97) 0.35 (0.14)
RIN −0.09 (0.70) −0.35 (0.14)
CDR 0.75 (2.2×10−4) 0.56 (0.014)
Plaque BM9 0.47 (0.045) 0.24 (0.32)
Plaque Meanc 0.56 (0.012) 0.36 (0.13)
Braak Stage 0.54 (0.017) 0.55 (0.015)
PMI=postmortem interval; RIN=RNA integrity number; CDR=clinical dementia rating; Plaque BM9=neuritic plaque density Brodmann area 9; 
Plaque Mean=mean of plaque densities measured in five cortical regions including Brodmann area 9 (middle frontal gyrus), Brodmann area 45/47 
(orbital frontal gyrus), Brodmann area 21/22 (superior temporal gyrus), Brodmann area 39 (inferior parietal cortex), and Brodmann area 17 
(calcarine cortex).
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